Author: Eoin Higgins,IT Brew

By Brianna Smith When COVID-19 overwhelmed hospitals across the country, Rebecca Dalton, a nurse, found herself pulled back into the frontlines of the ICU after spending years in patient education. She was having a hard time juggling pandemic care, while also raising her young children at home.Read More

Read More

MOUNTAIN VIEW, Calif., August 13, 2025–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.Read More

Read More

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functionRead More

Read More